In journal Cancer Research, researchers describe a new vulnerability of this cancer that can be targeted with a class of experimental drugs
Acute myeloid leukaemia (AML) is a blood cancer that causes an uncontrollable buildup of white blood cells.
Due to the poor outcomes of this disease, researchers all over the world have been looking for new ways to treat AML while still allowing normal blood development to occur.
In the journal Cancer Research, researchers from Baylor College of Medicine and other institutions describe a new vulnerability of this cancer that can be targeted with a class of experimental drugs.
These drugs target the SWI/SNF protein complex, which is used by many cells to make DNA more open and accessible. DNA accessibility has a significant impact on gene expression by regulating the cell's epigenetic state.
The authors show that drugs inhibiting SWI/SNF induce a profound therapeutic response in AML cell lines, animal models and human AML samples. In animals, this strategy caused rapid regression of the cancer within days. When authors compared their findings against AML cells to normal blood cells, they found that the drug targeting SWI/SNF caused specific changes to blood development. However, these side effects were manageable and quickly reversed after drug treatment. The results support further investigations on the use of this approach for AML.
"Our project set out to better understand a vulnerability in AML that could be exploited to treat the disease," said corresponding author, Dr. H. Courtney Hodges, assistant professor of molecular and cellular biology and member of the Dan L Duncan Comprehensive Cancer Center at Baylor.
In the course of the study, the scientists also discovered important mechanisms related to SWI/SNF. "We found that AML cells hijack a gene regulation program that involves SWI/SNF and another protein called PU.1. This program is normally used to make healthy white blood cells," said first author Courtney Chambers, a graduate student in the Hodges lab.
"Think of each cell's DNA as a huge labyrinth with many doors behind which are genes that contain instructions on how to make proteins," Hodges explained. "Most of these doors do not lead to genes of interest to a blood cell, so these cells need a way to know which doors lead to the specific genes they need. Here is where PU.1 plays a role."
"We found that PU.1 flags the doors that lead to genes of interest to certain blood cells," said Chambers. "In the case of AML cells, these flags mark genes that promote growth of AML, called oncogenes. PU.1 tags the doors but cannot open them, so SWI/SNF comes along." SWI/SNF is a protein complex that mediates access to DNA. After PU.1 tags a site of interest, SWI/SNF steps in and opens that door allowing expression of the oncogenes that sustain AML. The team found that some AML samples are much more dependent on this mechanism than normal blood cells.
Importantly, the researchers also discovered that drugs that block SWI/SNF's ability to open the door to gene activation in AML halt tumour growth by interfering with the expression of these oncogenes.
"It was very exciting to see how effective SWI/SNF inhibitors were to treat AML in animal models," Chambers said. "The effect was much more profound than we had expected." "AML is typically very hard to treat. The rapid tumor regression we saw in response to SWI/SNF inhibitors has encouraged us to continue our research into similar vulnerabilities of AML and other cancers," Hodges said.
No comments:
Post a Comment